Gynuity Health Projects

Programs

Misoprostol for Treatment of Incomplete Abortion

Traditionally, treatment of incomplete abortion in the first trimester involves either curettage or vacuum aspiration. Though highly effective these surgical procedures require trained providers, special equipment, sterile conditions, and often anesthesia. In settings with limited access to skilled providers and well-equipped facilities, use of misoprostol for medical management of incomplete abortion is an attractive alternative. Research has demonstrated that medical management of incomplete abortion is safe, effective, has a low incidence of side effects, and is highly acceptable to women.

Compelling evidence of misoprostol’s successful use in incomplete abortion has led Gynuity to further research optimal doses and routes of misoprostol administration for this indication and to conduct feasibility studies in a range of settings. Geographically, Gynuity’s research has expanded to Sub-Saharan Africa, Latin America and the Caribbean, and Eastern Europe/Former Soviet Union. Next steps will involve introducing misoprostol in rural settings and documenting its use in lower levels of the health care system.

Gynuity Activities
  • Partnership with public and private health care providers to introduce misoprostol for postabortion care into existing reproductive health services.
  • Collaboration with pharmaceutical companies to facilitate the registration of misoprostol for pregnancy failure internationally.
  • Provision of technical support to local governmental bodies to incorporate misoprostol regimens for postabortion care into technical guidelines and to improve existing protocols based on locally-generated clinical evidence.
  • Development of training and educational materials for policymakers, clinicians, and users.
  • Organization of seminars, educational opportunities and training courses to share information and stimulate interest in misoprostol’s potential.
  • Collaboration with the Postabortion Care Consortium on efforts to include misoprostol in standard PAC kits internationally.